X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA FRESENIUS KABI ONCO. DISHMAN PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 25.1 22.1 113.4% View Chart
P/BV x 3.3 3.1 107.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
DISHMAN PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs374176 212.7%   
Low Rs12979 164.2%   
Sales per share (Unadj.) Rs197.837.7 524.9%  
Earnings per share (Unadj.) Rs21.25.1 416.4%  
Cash flow per share (Unadj.) Rs34.76.7 516.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.942.5 422.8%  
Shares outstanding (eoy) m80.69158.23 51.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.7%   
Avg P/E ratio x11.925.0 47.5%  
P/CF ratio (eoy) x7.218.9 38.3%  
Price / Book Value ratio x1.43.0 46.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30620,135 100.8%   
No. of employees `0000.81.2 72.0%   
Total wages/salary Rs m5,355703 761.5%   
Avg. sales/employee Rs Th19,252.75,176.2 371.9%   
Avg. wages/employee Rs Th6,459.5610.4 1,058.2%   
Avg. net profit/employee Rs Th2,064.1699.6 295.0%   
INCOME DATA
Net Sales Rs m15,9615,963 267.7%  
Other income Rs m26518 1,474.4%   
Total revenues Rs m16,2265,981 271.3%   
Gross profit Rs m4,1031,430 286.9%  
Depreciation Rs m1,091258 422.9%   
Interest Rs m944-26 -3,632.3%   
Profit before tax Rs m2,3341,216 191.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m624342 182.2%   
Profit after tax Rs m1,711806 212.3%  
Gross profit margin %25.724.0 107.2%  
Effective tax rate %26.728.1 95.0%   
Net profit margin %10.713.5 79.3%  
BALANCE SHEET DATA
Current assets Rs m11,0185,102 216.0%   
Current liabilities Rs m9,5172,385 399.0%   
Net working cap to sales %9.445.6 20.6%  
Current ratio x1.22.1 54.1%  
Inventory Days Days110150 73.6%  
Debtors Days Days35113 30.7%  
Net fixed assets Rs m16,3045,148 316.7%   
Share capital Rs m161158 102.0%   
"Free" reserves Rs m12,9076,556 196.9%   
Net worth Rs m14,5166,732 215.6%   
Long term debt Rs m4,189952 440.0%   
Total assets Rs m29,80510,388 286.9%  
Interest coverage x3.5-45.8 -7.6%   
Debt to equity ratio x0.30.1 204.0%  
Sales to assets ratio x0.50.6 93.3%   
Return on assets %8.97.5 118.7%  
Return on equity %11.812.0 98.5%  
Return on capital %17.514.6 120.0%  
Exports to sales %24.874.5 33.3%   
Imports to sales %3.724.8 15.1%   
Exports (fob) Rs m3,9564,441 89.1%   
Imports (cif) Rs m5961,477 40.4%   
Fx inflow Rs m4,9525,298 93.5%   
Fx outflow Rs m6971,772 39.3%   
Net fx Rs m4,2553,525 120.7%   
CASH FLOW
From Operations Rs m2,7861,274 218.7%  
From Investments Rs m-1,529-1,204 127.0%  
From Financial Activity Rs m-941-196 479.9%  
Net Cashflow Rs m316-126 -250.5%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 12.7 9.6 132.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 9.1 242.9%  
Shareholders   46,261 42,599 108.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS